LY 3007113

Drug Profile

LY 3007113

Alternative Names: LY-3007113

Latest Information Update: 18 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 18 Sep 2013 Discontinued - Phase-I for Cancer (late-stage disease) in USA (PO)
  • 19 Dec 2011 Phase-I clinical trials in Cancer (late-stage disease) in USA (PO)
  • 06 May 2005 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top